(BCPC) Balchem - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0576652004
Choline, Encapsulated Nutrients, Sterilants, Propylene Oxide, Chelated Minerals
Dividends
| Dividend Yield | 0.58% |
| Yield on Cost 5y | 0.84% |
| Yield CAGR 5y | 10.67% |
| Payout Consistency | 96.3% |
| Payout Ratio | 17.5% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 22.7% |
| Value at Risk 5%th | 35.2% |
| Relative Tail Risk | -5.98% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.88 |
| Alpha | -25.07 |
| CAGR/Max DD | 0.23 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.515 |
| Beta | 0.548 |
| Beta Downside | 0.466 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.10% |
| Mean DD | 8.27% |
| Median DD | 8.16% |
Description: BCPC Balchem November 05, 2025
Balchem Corporation (NASDAQ: BCPC) manufactures specialty performance ingredients for a broad set of markets-including human nutrition, animal health, and industrial sterilization-organized into three operating segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
In FY 2023 the company generated roughly $2.2 billion in revenue, with an operating margin of about 12 % and a 5 % year-over-year increase driven primarily by higher demand for its vitamin K2 and microencapsulation platforms in functional foods and dietary supplements. A key sector catalyst is the accelerating consumer shift toward fortified, “clean-label” products, which is expanding the addressable market for Balchem’s spray-dried powders and lipid delivery systems. On the animal side, tighter regulations on antibiotic use are boosting adoption of chelated minerals and choline-based feed additives, supporting the segment’s double-digit growth trajectory.
For a deeper, data-rich assessment of Balchem’s valuation dynamics, you may find it worthwhile to explore the company’s profile on ValueRay, where additional quantitative metrics and scenario analyses are available.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (149.2m TTM) > 0 and > 6% of Revenue (6% = 60.8m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.44% (prev 22.98%; Δ -1.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 201.6m > Net Income 149.2m (YES >=105%, WARN >=100%) |
| Net Debt (90.7m) to EBITDA (260.1m) ratio: 0.35 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (32.7m) change vs 12m ago -0.25% (target <= -2.0% for YES) |
| Gross Margin 35.82% (prev 34.47%; Δ 1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 62.22% (prev 59.01%; Δ 3.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 18.82 (EBITDA TTM 260.1m / Interest Expense TTM 10.9m) >= 6 (WARN >= 3) |
Altman Z'' 7.23
| (A) 0.13 = (Total Current Assets 343.7m - Total Current Liabilities 126.4m) / Total Assets 1.66b |
| (B) 0.67 = Retained Earnings (Balance) 1.11b / Total Assets 1.66b |
| (C) 0.13 = EBIT TTM 204.3m / Avg Total Assets 1.63b |
| (D) 3.19 = Book Value of Equity 1.16b / Total Liabilities 363.2m |
| Total Rating: 7.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.50
| 1. Piotroski 8.0pt |
| 2. FCF Yield 3.14% |
| 3. FCF Margin 15.94% |
| 4. Debt/Equity 0.12 |
| 5. Debt/Ebitda 0.35 |
| 6. ROIC - WACC (= 3.38)% |
| 7. RoE 12.12% |
| 8. Rev. Trend 75.96% |
| 9. EPS Trend 82.22% |
What is the price of BCPC shares?
As of December 08, 2025, the stock is trading at USD 150.50 with a total of 179,986 shares traded.
Over the past week, the price has changed by -3.30%, over one month by -1.35%, over three months by -7.17% and over the past year by -14.02%.
Over the past week, the price has changed by -3.30%, over one month by -1.35%, over three months by -7.17% and over the past year by -14.02%.
Is BCPC a buy, sell or hold?
Balchem has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy BCPC.
- Strong Buy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BCPC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 200.7 | 33.3% |
| Analysts Target Price | 200.7 | 33.3% |
| ValueRay Target Price | 152.9 | 1.6% |
BCPC Fundamental Data Overview December 03, 2025
Market Cap USD = 5.05b (5.05b USD * 1.0 USD.USD)
P/E Trailing = 33.9804
P/E Forward = 30.2115
P/S = 4.9835
P/B = 3.898
P/EG = 4.8341
Beta = 0.994
Revenue TTM = 1.01b USD
EBIT TTM = 204.3m USD
EBITDA TTM = 260.1m USD
Long Term Debt = 154.0m USD (from longTermDebt, last quarter)
Short Term Debt = 202.0k USD (from shortTermDebt, last quarter)
Debt = 155.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 90.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.14b USD (5.05b + Debt 155.8m - CCE 65.1m)
Interest Coverage Ratio = 18.82 (Ebit TTM 204.3m / Interest Expense TTM 10.9m)
FCF Yield = 3.14% (FCF TTM 161.6m / Enterprise Value 5.14b)
FCF Margin = 15.94% (FCF TTM 161.6m / Revenue TTM 1.01b)
Net Margin = 14.72% (Net Income TTM 149.2m / Revenue TTM 1.01b)
Gross Margin = 35.82% ((Revenue TTM 1.01b - Cost of Revenue TTM 650.5m) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 36.45%)
Tobins Q-Ratio = 3.10 (Enterprise Value 5.14b / Total Assets 1.66b)
Interest Expense / Debt = 1.51% (Interest Expense 2.35m / Debt 155.8m)
Taxrate = 22.59% (11.8m / 52.0m)
NOPAT = 158.2m (EBIT 204.3m * (1 - 22.59%))
Current Ratio = 2.72 (Total Current Assets 343.7m / Total Current Liabilities 126.4m)
Debt / Equity = 0.12 (Debt 155.8m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.35 (Net Debt 90.7m / EBITDA 260.1m)
Debt / FCF = 0.56 (Net Debt 90.7m / FCF TTM 161.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.98% (Net Income 149.2m / Total Assets 1.66b)
RoE = 12.12% (Net Income TTM 149.2m / Total Stockholder Equity 1.23b)
RoCE = 14.75% (EBIT 204.3m / Capital Employed (Equity 1.23b + L.T.Debt 154.0m))
RoIC = 11.20% (NOPAT 158.2m / Invested Capital 1.41b)
WACC = 7.82% (E(5.05b)/V(5.21b) * Re(8.03%) + D(155.8m)/V(5.21b) * Rd(1.51%) * (1-Tc(0.23)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.35%
[DCF Debug] Terminal Value 80.77% ; FCFE base≈162.0m ; Y1≈190.6m ; Y5≈291.5m
Fair Price DCF = 154.3 (DCF Value 5.00b / Shares Outstanding 32.4m; 5y FCF grow 18.81% → 3.0% )
EPS Correlation: 82.22 | EPS CAGR: 13.13% | SUE: 4.0 | # QB: 2
Revenue Correlation: 75.96 | Revenue CAGR: 6.25% | SUE: 1.65 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.53 | Chg30d=+0.025 | Revisions Net=+1 | Growth EPS=+7.8% | Growth Revenue=+6.3%
P/E Trailing = 33.9804
P/E Forward = 30.2115
P/S = 4.9835
P/B = 3.898
P/EG = 4.8341
Beta = 0.994
Revenue TTM = 1.01b USD
EBIT TTM = 204.3m USD
EBITDA TTM = 260.1m USD
Long Term Debt = 154.0m USD (from longTermDebt, last quarter)
Short Term Debt = 202.0k USD (from shortTermDebt, last quarter)
Debt = 155.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 90.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.14b USD (5.05b + Debt 155.8m - CCE 65.1m)
Interest Coverage Ratio = 18.82 (Ebit TTM 204.3m / Interest Expense TTM 10.9m)
FCF Yield = 3.14% (FCF TTM 161.6m / Enterprise Value 5.14b)
FCF Margin = 15.94% (FCF TTM 161.6m / Revenue TTM 1.01b)
Net Margin = 14.72% (Net Income TTM 149.2m / Revenue TTM 1.01b)
Gross Margin = 35.82% ((Revenue TTM 1.01b - Cost of Revenue TTM 650.5m) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 36.45%)
Tobins Q-Ratio = 3.10 (Enterprise Value 5.14b / Total Assets 1.66b)
Interest Expense / Debt = 1.51% (Interest Expense 2.35m / Debt 155.8m)
Taxrate = 22.59% (11.8m / 52.0m)
NOPAT = 158.2m (EBIT 204.3m * (1 - 22.59%))
Current Ratio = 2.72 (Total Current Assets 343.7m / Total Current Liabilities 126.4m)
Debt / Equity = 0.12 (Debt 155.8m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.35 (Net Debt 90.7m / EBITDA 260.1m)
Debt / FCF = 0.56 (Net Debt 90.7m / FCF TTM 161.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.98% (Net Income 149.2m / Total Assets 1.66b)
RoE = 12.12% (Net Income TTM 149.2m / Total Stockholder Equity 1.23b)
RoCE = 14.75% (EBIT 204.3m / Capital Employed (Equity 1.23b + L.T.Debt 154.0m))
RoIC = 11.20% (NOPAT 158.2m / Invested Capital 1.41b)
WACC = 7.82% (E(5.05b)/V(5.21b) * Re(8.03%) + D(155.8m)/V(5.21b) * Rd(1.51%) * (1-Tc(0.23)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.35%
[DCF Debug] Terminal Value 80.77% ; FCFE base≈162.0m ; Y1≈190.6m ; Y5≈291.5m
Fair Price DCF = 154.3 (DCF Value 5.00b / Shares Outstanding 32.4m; 5y FCF grow 18.81% → 3.0% )
EPS Correlation: 82.22 | EPS CAGR: 13.13% | SUE: 4.0 | # QB: 2
Revenue Correlation: 75.96 | Revenue CAGR: 6.25% | SUE: 1.65 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.53 | Chg30d=+0.025 | Revisions Net=+1 | Growth EPS=+7.8% | Growth Revenue=+6.3%
Additional Sources for BCPC Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle